PROGNOSTIC VALUE OF SOLUBLE CD40 LIGAND AFTER LIVER TRANSPLANTATION IN CHILDREN WITH CONGENITAL AND HEREDITARY DISEASES OF HEPATOBILIARY SYSTEM
https://doi.org/10.15825/1995-1191-2012-2-15-19
Abstract
The aim of the study was to evaluate plasma levels of sCD40L in children before and after living donor liver transplantation (LDLT) and its prognostic value with postoperative course. The study included 67 children with end-stage liver disease (ESLD), aged from 4 to 36 months before and after LDLT, 25 healthy children aged from 7 to 24 months and 38 adult living-related liver donors, aged from 18 to 56 years.
In children with ESLD pre-transplant plasma level of sCD40L (3.3 ± 2.2 ng/ml) did not differ in children with and without liver disease but were significantly higher in patients with end-stage liver disease than in donors (4.1 ± 2.3 ng/ml and 1.07 ± 1.1 ng/ml, resp., p < 0.01).
Graft dysfunction frequency was significantly higher in recipients with high sCD40L level (≥3.3 ng/ml). A mea- surement of pre-transplant sCD40L concentrations might be useful to identify patients with ESLD at high risk for graft dysfunction development.
About the Authors
O. P. Shevchenko
Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow
O. M. Tsirulnikova
Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow
O. E. Gichkun
Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow
Russian Medical Academy of Postgraduate Education, Moscow
L. V. Makarova
Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow
I. E. Tsirulnikova
Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow
D. G. Akhaladze
Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow
N. P. Shmerko
Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow
S. V. Gautier
Academician V.I. Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow
References
1. Готье С.В., Константинов Б.А., Цирульникова О.М. Трансплантация печени // М.: Медицинское инфор- мационное агентство. 2008. 296 с.
2. Шевченко О.П., Орлова О.В., Казаков Э.Н. и др. Кли- ническое значение растворимого лиганда CD40 у реципиентов сердца // Вестник трансплантологии и искусственных органов. 2009. No 1. С. 40–45.
3. Шевченко О.П., Орлова О.В., Халилулин Т.А. Имму- носупрессия, иммунная толерантность и костимуляция Т-лимфоцитов // Иммуносупрессия при транс- плантации солидных органов; под ред. С.В. Готье. М.–Тверь: Триада. 2011. С. 423–470.
4. Шевченко О.П., Цирульникова О.М., Олефиренко Г.А. и др. Уровень sCD30 при трансплантации печени у детей с врожденными и наследственными заболеваниями пе- чени и желчевыводящих путей // Вестник трансплан- тологии и искусственных органов. 2011. No 4. С. 37–43.
5. Contin C., Pitako V., Delmes Y. et al. Potential role of sCD40L in the humoral immune response impairment of uraemic patients // Immunology. 2003. Vol. 110 (1). P. 131–140.
6. Antoniades C., Bakogiannis C., Tousoulis D. et al. The CD40/CD40L system linking inflammation with atherothrombosis // J. Am. Coll. Cardiol. 2009. Vol. 54 (8). P. 669–677.
7. Gaweco A.S., Wiesner R.H., Yong S. et al. CD40L (CD154) expression in Human liver allograft during chronic ductopenic rejection // Liver transplantation and surgery. 1999. Vol. 5. No 1. P. 1–7.
8. Gaweco A.S., Wiesner R.H., Yong S. et al. Kupffer Cell expression of CD40L (CD154) in Human Chronic Liver
9. Allograft Rejection // Transplantation proceedings.
10. Vol. 31. P. 560–561.
11. Jung D.Y., Kim E.Y., Joo S.Y. et al. Prolonged survival of
12. islet allografts in mice treated with rosmarinic acid and
13. antiCD154 antibody/Exp Mol Med. 2008. Vol. 40. P. 1.
14. Larsen C.P., Alexander D.Z., Hollenbaugh D. et al. CD40-gp39 interactions play a critical role during al- lograft rejection. Suppression of allograft rejection by blockade of the CD40-gp39 pathway // Transplantation.
15. Vol. 61. P. 4–9.
16. Muiesan P., Vergani D., Mieli-Vergani G. Liver transplan-
17. tation in children // J. Hepatol. 2007. Vol. 2. P. 340–348.
18. Oertelt S., Invernizzi P., Selmi C. et al. Soluble CD40L in plasma of patients with primary biliary cirrhosis // Ann
19. NY Acad Sci. 2005. Vol.1051. P. 205–210.
20. Van Kooten C., Banchereau J. CD40-CD40 ligand // J. of
21. Leukocyte biology. – 2000. Vol. 67. P. 2–17.
22. Xiuda Shen, Yue Wang, Feng Gao, Feng Ren. CD4 T Cells Promote Tissue Inflammation via CD40 Signa- ling Without De Novo Activation in a Murine Model of Liver Ischemia/Reperfusion Injury // Hepatology. 2009.
23. P. 1537–1546.
Review
For citations:
Shevchenko O.P., Tsirulnikova O.M., Gichkun O.E., Makarova L.V., Tsirulnikova I.E., Akhaladze D.G., Shmerko N.P., Gautier S.V. PROGNOSTIC VALUE OF SOLUBLE CD40 LIGAND AFTER LIVER TRANSPLANTATION IN CHILDREN WITH CONGENITAL AND HEREDITARY DISEASES OF HEPATOBILIARY SYSTEM. Russian Journal of Transplantology and Artificial Organs. 2012;14(2):15-19. (In Russ.) https://doi.org/10.15825/1995-1191-2012-2-15-19
Views:
748
Email this article 